Consensus recommendations for the management of chronic heart failure: Introduction

American Journal of Cardiology

Volumn 83, Issue 2 A, 1999, Pages

  Packer, Milton ^a   Cohn, Jay N ^b   Abraham, William T ^e   Colucci, Wilson S ^e   Fowler, Michael B ^e   Greenberg, Barry H ^c   Leier, Carl V ^e   Massie, Barry M ^d   Young, James B ^e   Aaronson, Keith D ^e   Abrams, Jonathan ^e   Adams, Kirkwood F ^e   Alpert, Joseph S ^e   Anand, Inder S ^e   Armstrong, Paul W ^e   Baker, David W ^e   Bank, Alan J ^e   Beller, George A ^e   Borer, Jeffrey S ^e   Bourge, Robert C ^e   Burnett, John C ^e   Carabello, Blase A ^e   Carson, Peter E ^e   Chatterjee, Kanu ^e   Cintron, Guillermo B ^e   Cody, Robert J ^e   Conti, C Richard ^e   Costanzo, Maria Rosa ^e   Creager, Mark A ^e   Curry, Charles L ^e   Dec, G William ^e   Deedwania, Prakash C ^e   Dell'Italia, Louis ^e   De Marchena, Eduardo ^e   De Marco, Teresa ^e   DeMaria, Anthony N ^e   DiBianco, Robert ^e   Donohue, Thomas J ^e   Douglass, Paul ^e   Dunkman, W Bruce ^e   Elkayam, Uri ^e   Falk, Rodney H ^e   Feldman, Arthur M ^e   Ferdinand, Keith C ^e   Fletcher, Ross D ^e   Fonarow, Gregg C ^e   Franciosa, Joseph ^e   Francis, Gary S ^e   Frantz, Robert P ^e   Gaasch, William H ^e   Geltman, Edward M ^e   Gheorghiade, Mihai ^e   Gilbert, Edward Michael ^e   Giles, Thomas D ^e   Givertz, Michael M ^e   Goldman, Steven ^e   Goldsmith, Steven R ^e   Goldstein, Sidney ^e   Gottlieb, Stephen S ^e   Gradman, Alan H ^e   Gregory, John J ^e   Haeusslein, Ernie ^e   Hargrove, Joe L ^e   Hermann, Denise D ^e   Hershberger, Ray ^e   Heywood, J Thomas ^e   Higginbotham, Michael B ^e   Hill, James A ^e   Hood, William B ^e   Hosenpud, Jeffrey D ^e   Jafri, Syed A Q ^e   James, Frank S ^e   Jessup, Mariell ^e   Johnston, Thomas S ^e   Jugdutt, Bodh I ^e   Kahl, Frederic R ^e   Kantrowitz, Niki E ^e   Kasper, Edward K ^e   Katz, Arnold M ^e   Katz, Richard J ^e   Katz, Stuart D ^e   Kirlin, Philip C ^e   Kohn, Robert M ^e   Konstam, Marvin A ^e   Kostis, John B ^e   Kowey, Peter R ^e   Krueger, Steven K ^e   Kukin, Marrick L ^e   Kumpuris, Andrew G ^e   Le Jemtel, Thierry ^e   Lee, Forrester A ^e   Levine, T Barry ^e   Liang, Chang seng ^e   Loeb, Henry S ^e   Loh, Evan ^e   Lorell, Beverly H ^e   Lutz, Jerre ^e   Mallis, George I ^e   Mancini, Donna M ^e   more..

^a New York Presbyterian Columbia University Medical Center   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDRALAZINE; ISOSORBIDE DINITRATE; NONSTEROID ANTIINFLAMMATORY AGENT; SOTALOL; VASODILATOR AGENT;

DISEASE CLASSIFICATION; DISEASE SEVERITY; EDITORIAL; ELECTROLYTE BALANCE; HEALTH CARE POLICY; HEART FAILURE; HUMAN; MORTALITY; PATHOPHYSIOLOGY; PATIENT SELECTION; PRIORITY JOURNAL; PUBLIC HEALTH;

EID: 0033590646     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00850-9     Document Type: Letter

References (404)

1. 1. Heart Failure Guideline Panel. Heart Failure: Evaluation and Care of Patients With Left Ventricular Systolic Dysfunction. Rockville, Md: US Dept of Health and Human Services, Agency for Health Care Policy and Research; 1994. Clinical Practice Guideline Number 11. AHCPR Publication 94-0612.
2. 2. ACC/AHA Task Force on Practice Guidelines. Guidelines for the evaluation and management of heart failure. Circulation 1995;92:2764-2784.
3. 3. Task Force of the Working Group on Heart Failure of the European Society of Cardiology. The treatment of heart failure. Eur Heart J 1997;18:736-753.
4. 4. World Health Organization Council on Geriatric Cardiology. Task Force on Heart Failure Education. Concise guide to the management of heart failure. J Card Failure 1996;2:153-154.
5. 5. American Heart Association. 1998 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association; 1997.
6. 6. Massie BM, Shah NB. Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. Am Heart J 1997;133:703-712.
7. 7. O'Connell JB, Bristow MR. Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant 1994;13:S107-S112.
8. 8. Ho KKL, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham study. J Am Coll Cardiol 1993;22(suppl A):6A-13A.
9. 9. Gooding J, Jette AM. Hospital readmissions among the elderly. J Am Geriatr Soc 1985;33:595-601.
10. 10. Rich MW, Freedland KE. Effect of DRGs on three-month readmission rate of geriatric patients with congestive heart failure. Am J Public Health 1988;78:680-682.
11. 11. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992;20:248-254.
12. 12. Packer M. How should physicians view heart failure? The philosophical and physiological evolution of three conceptual models of the disease. Am J Cardiol 1993;71(suppl):3C-11C.
13. 13. Massie BM. Exercise tolerance in congestive heart failure: role of cardiac function, peripheral blood flow and muscle metabolism and effect of treatment. Am J Med 1988;84(suppl 3A):75-82.
14. 14. Smith RF, Johnson G, Ziesche S, Bhat G, Blankenship K, Cohn JN, for the V-HeFT VA Cooperative Studies Group. Functional capacity in heart failure. Comparison of methods of assessment and their relation to other indexes of heart failure. Circulation 1993;87(suppl VI):VI-88-VI-93.
15. 15. Franciosa JA, Park M, Levine TB. Lack of correlation between exercise capacity and indexes of resting left ventricular performance in heart failure. Am J Cardiol 1981;47:33-39.
16. 16. Packer M. Abnormalities of diastolic function as a potential cause of exercise intolerance in chronic heart failure. Circulation 1990;81(suppl II):III78-III86.
17. 17. Wilson JR, Mancini DM, Dunkman WB. Exertional fatigue due to skeletal muscle dysfunction in patients with heart failure. Circulation 1993;87:470-475.
18. 18. Wilson JR, Martin JL, Ferraro N. Impaired skeletal muscle nutritive flow during exercise in patients with congestive heart failure: role of cardiac pump dysfunction as determined by the effect of dobutamine. Am J Cardiol 1984;53: 1308-1315.
19. 19. Mancini DM, Henson D, LaManca J, Levine S. Respiratory muscle function and dyspnea in patients with chronic congestive heart failure. Circulation 1992; 86:909-918.
20. 20. Mancini DM. Pulmonary factors limiting exercise capacity in patients with heart failure. Prog Cardiovasc Dis 1995;37:347-370.
21. 21. Wilson JR, Frey MJ, Mancini DM, Ferraro N, Jones R. Sympathetic vasoconstriction during exercise in ambulatory patients with left ventricular failure. Circulation 1989;79:1021-1027.
22. 22. Hirsch AT, Dzau VJ, Creager MA. Baroreceptor function in congestive heart failure: effect on neurohumoral activation and regional vascular resistance. Circulation 1987;75(suppl IV):IV36-IV48.
23. 23. Sullivan MJ, Knight JD, Higginbotham MB, Cobb FR. Relation between central and peripheral hemodynamics during exercise in patients with chronic heart failure. Muscle blood flow is reduced with maintenance of arterial perfusion pressure. Circulation 1989;80:769-781.
24. 24. Massie BM, Kramer BL, Topic N. Lack of relationship between the short-term hemodynamic effects of captopril and subsequent clinical responses. Circulation 1984;69:1135-1141.
25. 25. Mancini DM, Schwartz M, Ferraro N, Seestedt R, Chance B, Wilson JR. Effect of dobutamine on skeletal muscle metabolism in patients with congestive heart failure. Am J Cardiol 1990;65:1121-1126.
26. 26. Drexler H, Banhardt U, Meinertz T, Wollschlager H, Lehmann M, Just H. Contrasting peripheral short-term and long-term effects of converting enzyme inhibition in patients with congestive heart failure: a double-blind, placebo-controlled trial. Circulation 1989;79:491-502.
27. 27. Khan T, Levin HR, Oz MC, Katz SD. Delayed reversal of impaired metabolic vasodilation in patients with end-stage heart failure during long-term circulatory support with a left ventricular assist device. J Heart Lung Transplant 1997; 16:443-453.
28. 28. Franciosa JA, Goldsmith SR, Cohn JN. Contrasting immediate and long-term effects of isosorbide dinitrate on exercise capacity in congestive heart failure. Am J Med 1980;69:559-566.
29. 29. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction: experimental observations and clinical implications. Circulation 1990;81: 1161-1172.
30. 30. Cohn JN. Structural basis for heart failure: ventricular remodeling and its pharmacologic inhibition. Circulation 1995;91:2504-2507.
31. 31. Pfeffer JM, Pfeffer MA, Braunwald E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res 1985;57:84-95.
32. 32. Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med 1988;319:80-86.
33. 33. Sabbah HN, Shimoyama H, Kono T, Gupta RC, Sharov VG, Scicli G, Levine TB, Goldstein S. Effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction. Circulation 1994;89:2852-2859.
34. 34. McDonald KM, Rector T, Carlyle PF, Francis GS, Cohn JN. Angiotensin-converting enzyme inhibition and beta-adrenoceptor blockade regress established ventricular remodeling in a canine model of discrete myocardial damage. J Am Coll Cardiol 1994;24:1762-1768.
35. 35. Mulder P, Richard V, Derumeaux G, Hogie M, Henry JP, Lallemand F, Compagnon P, Mace B, Comoy E, Letac B, Thuillez C. Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation 1997;96:1976-1982.
36. 36. Francis GS, Goldsmith SR, Levine TB, Olivari MT, Cohn JN. The neurohumoral axis in congestive heart failure. Ann Intern Med 1984;101:370-377.
37. 37. Pousset F, Isnard R, Lechat P, Kalotka H, Carayon A, Maistre G, Escolano S, Thomas D, Komajda M. Prognostic value of plasma endothelin-1 in patients with chronic heart failure. Eur Heart J 1997;18:254-258.
38. 38. Mann DL, Kent RL, Parsons B, Cooper G IV. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 1992;85:790-804.
39. 39. Tan LB, Jalil JE, Pick R, Janicki JS, Weber KT. Cardiac myocyte necrosis induced by angiotensin II. Circ Res 1991;69:1185-1195.
40. 40. Sabbah HN, Sharov VG. Apoptosis in heart failure. Prog Cardiovasc Dis 1998;40:549-562.
41. 41. Goussev A, Sharov VG, Shimoyama H, Tanimura M, Lesch M. Effects of ACE inhibition on cardiomyocyte apoptosis in dogs with heart failure. Am J Physiol 1998;275:H626-H631.
42. 42. Feuerstein G, Yue TL. Novel mechanisms in the treatment of heart failure: inhibition of oxygen radicals and apoptosis by carvedilol. Prog Cardiovasc Dis 1998;48(suppl 1): 17-24.
43. 43. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;323:236-241.
44. 44. Mann DL. The effect of tumor necrosis factor-alpha on cardiac structure and function; a tale of two cytokines. J Card Failure 1996;2(suppl 4):S165-S172.
45. 45. Ono K, Matsumori A, Shioi T, Furukawa Y, Sasayama S. Cytokine gene expression after myocardial infarction in rat hearts: possible implication in left ventricular remodeling. Circulation 1998;98:149-156.
46. 46. Zhou G, Kandala JC, Tyagi SC, Katwa LC, Weber KT. Effects of angiotensin II and aldosterone on collagen gene expression and protein turnover in cardiac fibroblasts. Mol Cell Biochem 1996;154:171-178.
47. 47. Weber KT. Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation 1997;96:4065-4082.
48. 48. Yue P, Massie BM, Simpson PC, Long CS. Cytokine expression increases in nonmyocytes from rats with postinfarction heart failure. Am J Physiol 1998;275: H250-H258.
49. 49. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, Mallis GI, Sollano JA, Shannon J, Tandon PK, DeMets DL, for the PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991;325:1468-1475.
50. 50. Cowley AJ, Skene AM. Treatment of severe heart failure: quantity or quality of life? A trial of enoximone. Enoximone Investigators. Br Heart J 1994;72:226-230.
51. 51. Hampton JR, van Veldhuisen DJ, Kleber FX, Cowley AJ, Ardia A, Block P, Cortina A, Cserhalmi L, Follath F, Jensen G, Kayanakis J, Lie KI, Mancia G, Skene AM, for the Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Lancet 1997;349:971-977.
52. 52. Packer M, Narahara KA, Elkayam U, Sullivan JM, Pearle DL, Massie BM, Creager MA, and the Principal Investigators of the REFLECT Study. Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. J Am Coll Cardiol 1993;22:65-72.
53. 53. Packer M, Rouleau J-L, Swedberg K, Pitt B, Fisher L, Klepper M, and the PROFILE Investigators and Coordinators. Effect of flosequinan on survival in chronic heart failure: preliminary results of the PROFILE study. (ABstr.) Circulation 1993;88(suppl 1):301.
54. 54. Califf RM, Adams KF, McKenna WJ, Gheorgiade M, Uretky BF, McNulty SE, Darius H, Schulman K, Zannad F, Handberg-Thurmond E, Harrell FE Jr, Wheeler W, Soler-Soler J, Swedberg K. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997;134:44-54.
55. 55. Konstam MA, Kronenberg MW, Rousseau MF, Udelson JE, Melin J, Stewart D, Dolan N, Edens TR, Ahn S, Kinan D, Howe DM, Kilcoyne L, Metherall J, Benedict C, Yusuf S, Pouleur H, for the SOLVD Investigators. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. Circulation 1993;88:2277-2283.
56. 56. Australia-New Zealand Heart Failure Research Collaborative Group. Effects of carvedilol, a vasodilator-β-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation 1995;92:212-218.
57. 57. Jugdutt BI, Khan MI. Effect of prolonged nitrate therapy on left ventricular remodeling after canine myocardial infarction. Circulation 1994;89:2297-2307.
58. 58. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995;273:1450-1456.
59. 59. Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel J-P. Clinical effects of β-adrenergic blockade in chronic heart failure. A meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 1998;98:1184-1191.
60. 60. Eichhorn EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart: a new era in the treatment of heart failure. Circulation 1996;94:2285-2296.
61. 61. DiCarli MF, Asgarzadie F, Schelbert HR, Brunken RC, Laks H, Phelps ME, Maddahi J. Quantitative relation between myocardial viability and improvement in heart failure symptoms after revascularization in patients with ischemic cardiomyopathy. Circulation 1995;92:3436-3444.
62. 62. Alderman EL, Fisher LD, Litwin P, Kaiser GC, Myers WO, Maynard C, Levine F, Schloss M. Results of coronary artery surgery in patients with poor left ventricular function (CASS). Circulation 1983;68:785-795.
63. 63. Elefteriades JA, Tolis G Jr, Levi E, Mills LK, Zaret BL. Coronary artery bypass grafting in severe left ventricular dysfunction: excellent survival with improved ejection fraction and functional state. J Am Coll Cardiol 1993;22:1411-1417.
64. 64. Pagano D, Bonser RS, Townlend JN, Ordoubadi F, Lorenzoni R, Camici PG. Predictive value of dobutamine echocardiography and positron emission tomography in identifying hibernating myocardium in patients with post-ischemic heart failure. Heart 1998;79:281-288.
65. 65. Baker DW, Jones R, Hodges J, Massie BM, Konstam MA, Rose EA. Management of heart failure. III. The role of revascularization in the treatment of patients with moderate or severe left ventricular systolic dysfunction. JAMA 1994;272:1528-1534.
66. 66. Chow LC, Dittrich HC, Shabetai R. Endomyocardial biopsy in patients with unexplained heart failure. Ann Intern Med 1988;109:535-539.
67. 67. Starling RC, VanFossen DB, Hammer DF, Unverferth DV. Morbidity of endomyocardial biopsy in cardiomyopathy. Am J Cardiol 1991;68:133-136.
68. 68. Parrillo JE, Aretz HT, Palacios I, Fallon JT, Block PC. The results of transvenous endomyocardial biopsy can frequently be used to diagnose myocardial diseases in patients with idiopathic heart failure. Endomyocardial biopsies in 100 consecutive patients revealed a substantial incidence of myocarditis. Circulation 1984;69:93-101.
69. 69. Cintron G, Johnson G, Francis G, Cobb F, Cohn JN. Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 1993; 87(suppl VI):VI-17-VI-23.
70. 70. St John Sutton M, Pfeffer MA, Plappert T, Rouleau JL, Moye LA, Dagenais GR, Lamas GA, Klein M, Sussex B, Goldman S, Menapace FJ Jr, Parker JO, Lewis S, Sestier F, Gordon DF, McEwan P, Bernstein V, Braunwald E, for the SAVE Investigators. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation 1994;89:68-75.
71. 71. Weber KT, Wilson JR, Janicki JS, Likoff MJ. Exercise testing in the evaluation of the patient with chronic cardiac failure. Am Rev Respir Dis 1984; 129:S60-S62.
72. 72. Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 7th ed. Boston: Little, Brown, 1973:286.
73. 73. Guyatt GH, Sullivan MJ, Thompson PJ, Fallen EL, Pugsley SO, Taylor DW, Berman LB. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 1985;132:919-923.
74. 74. Rector T, Kubo S, Cohn JN. Patients self-assessment of their congestive heart failure. Part 2: content, reliability and validity of a new measure. The Minnesota Living with Heart Failure Questionnaire. Heart Failure 1987;3:198-209.
75. 75. Gorkin L, Norvell NK, Rosen RC, Charles E, Shumaker SA, McIntyre KM, Capone RJ, Kostis J, Niaura R, Woods P, Hosking J, Garces C, Handberg E, Ahern DK, Follick MJ, for the SOLVD Investigators. Assessment of quality of life as observed from the baseline data of the Studies of Left Ventricular Dysfunction (SOLVD) Trial quality-of-life substudy. Am J Cardiol 1993;71: 1069-1073.
76. 76. LeJemtel TH, Liang CS, Stewart DK, Lirlin PC, McIntyre KM, Robertson TH, Moore A, Cahill L, Galvao M, Wellington KL, Garces C, Held P, for the SOLVD Investigators. Reduced peak aerobic capacity in asymptomatic left ventricular systolic dysfunction. A substudy of the Studies of Left Ventricular Dysfunction. Circulation 1994;90:2757-2760.
77. 77. Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LH Jr, Wilson JR. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 1991;83: 778-786.
78. 78. Cohn JN. Jugular venous pressure monitoring: a lost art? J Card Failure 1997;3:71-73.
79. 79. Pittman JG, Cohen P. The pathogenesis of cardiac cachexia. N Engl J Med 1964;271:403-409.
80. 80. Packer M. How should we judge the efficacy of drug therapy in patients with chronic congestive heart failure? The insights of six blind men. J Am Coll Cardiol 1987;9:433-438.
81. 81. Packer M. The placebo effect in heart failure. Am Heart J 1990;120:1579-1582.
82. 82. Russell SD, McNeer FR, Beere PA, Logan LJ, Higginbotham MB. Improvement in the mechanical efficiency of walking: an explanation for the placebo effect seen during repeated exercise testing of patients with heart failure. Am Heart J 1998;135:107-114.
83. 83. Guyatt GH, Pugsley SO, Sullivan MJ, Thompson PJ, Jones NL, Fallen EL, Taylor DW. Effect of encouragement on walking test performance. Thorax 1984;39:818-822.
84. 84. Goldsmith RL, Krum H, Sackner-Bernstein J, Schwanz B, Neuberg GW, Penn J, Kukin ML, Packer M. Do changes in exercise tolerance reflect the clinical response to therapy in patients with heart failure? Implications for the design of clinical trials. (Abstr.) Circulation 1992;86(suppl 1):1-513.
85. 85. Sable DL, Brammell HL, Sheehan MW, Nies AS, Gerber J, Horwitz LD. Attenuation of exercise conditioning by beta-adrenergic blockade. Circulation 1982;65:679-684.
86. 86. Kubo SH, Gollub S, Bourge R, Rahko P, Cobb F, Jessup M, Brozena S, Brodsky M, Kirlin P, Shanes J, Konstam M, Gradman A, Morledge J, Cinquegrani M, Singh S, LeJemtel T, Nicklas J, Troha J, Cohn JN, for the Pimobendan Multicenter Research Group. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure: results of a multicenter trial. Circulation 1992;85:942-949.
87. 87. Packer M, Gheorghiade M, Young JB, Costantini PJ, Adams KF, Cody RJ, Smith LK, Van Voorhees L, Gourley LA, Jolly MK, for the RADIANCE Study. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-convcrting enzyme inhibitors. N Engl J Med 1993;329:1-7.
88. 88. Rogers WJ, Johnstone DE, Yusuf S, Weiner DH, Gallagher P, Bittner VA, Ahn S, Schron E, Shumaker SA, Sheffield LT. Quality of life among 5,025 patients with left ventricular dysfunction randomized between placebo and enalapril: the Studies of Left Ventricular Dysfunction. The SOLVD Investigators. J Am Coll Cardiol 1994;23:393-400.
89. 89. Packer M, Colucci WS, Sackner-Bernstein JD, Liang C, Goldscher DA, Freeman I, Kukin ML, Kinhal V, Udelson JE, Klapholz M, Gottlieb SS, Pearle D, Cody RJ, Gregory JJ, Kantrowitz NE, LeJemtel TH, Young ST, Lukas MA, Shusterman NH, for the PRECISE Study Group. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. Circulation 1996;94:2793-2799.
90. 90. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N, for the MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94:2807-2816.
91. 91. Packer M. End of the oldest controversy in medicine: are we ready to conclude the debate on digitalis? N Engl J Med 1997;336:575-576.
92. 92. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-691.
93. 93. Scandinavian Simvaslatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
94. 94. Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Pyorala K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Failure 1997;3:249-254.
95. 95. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 1970; 213:1143-1152.
96. 96. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265: 3255-3264.
97. 97. Kostis JB, Davis BR, Cutler J, Grimm RH Jr, Berge KG, Cohen JD, Lacy CR, Perry HM Jr, Blaufox MD, Wassertheil-Smoller S, Black HR, Schron E, Berkson DM, Curb JD, Smith WM, McDonald R, Applegate WB, for the SHEP Cooperative Research Group. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1997;278: 212-216.
98. 98. Guerci AD, Gerstenblith G, Brinker JA, Chandra NC, Gottlieb SO, Bahr RD, Weiss JL, Shapiro EP, Flaherty JT, Bush DE, Chew PH, Gottlieb SH, Halperin HR, Ouyang P, Walford D, Bell WR, Fatterpaker AK, Llewellyn M, Topol EJ, Healy B, Siu CD, Becker LC, Weisfeldt ML. A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty. N Engl J Med 1987;317:1613-1618.
99. 99. Gruppo Italiano per lo Studio della Sopravivenza nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397-401.
100. 100. ISIS-2 (Second International Study of Infarct Survival Collaborative Group). Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 1988;2:349-360.
101. 101. The TIMT Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) phase II trial. N Engl J Med 1989;320:618-627.
102. 102. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival Collaborative Group). Lancet 1995;345:669-685.
103. 103. Gruppo Italiano per lo Studio della Sopravvivenza nell' Infarto Miocardico. GISSI-3. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-1122.
104. 104. Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981;304:801-807.
105. 105. Beta Blocker Heart Attack Study Group. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982; 247:1707-1714.
106. 106. The Acute Infarction Ramipril Efficacy (ATRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-828.
107. 107. Chadda K, Goldstein S, Byington R, Curb JD. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 1986;73:503-510.
108. 108. Vantrimpont P, Rouleau JL, Wun CC, Ciampi A, Klein M, Sussex B, Arnold JM, Moye L, Pfeffer M, for the SAVE Investigators. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. J Am Coll Cardiol 1997;29:229-236.
109. 109. Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
110. 110. Pfeffer MA, Braunwald E, Moy LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM, on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med 1992;327:669-677.
111. 111. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC, Aliot E, Persson S, Camm AJ, for the Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting-cnzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995;333:1670-1676.
112. 112. Sullivan MJ, Higginbotham MB, Cobb FR. Exercise training in patients with chronic heart failure delays vcntilatory anaerobic threshold and improves submaximal exercise performance. Circulation 1989;79:324-329.
113. 113. Coates AJS, Adamopoulos S, Radaelli A, McCance A, Meyer TE, Bernardi L, Solda PL, Davey P, Ormerod O, Forfar C, Conway J, Sleight P. Controlled trial of physical training in chronic heart failure: exercise performance, hemodynamics, ventilation, and autonomic function. Circulation 1992;85:2119-2131.
114. 114. Temporelli PL, Giannuzzi P, Corra U, Balestroni G, Tavazzi L, for the ELVD-CHF Study Group. Long-term exercise training in patients with chronic heart failure: results of the ELVD-CHF (exercise in left ventricular dysfunction and chronic heart failure) trial. (Abstr.) Eur Heart J 1998;19(suppl):3.
115. 115. Sindone A, Baker V, Sammel N, Keogh A, MacDonald P. Long-term follow-up of patients randomised to exercise training and cardiac rehabitation in moderate heart failure. (Abstr.) Eur Heart J 1998;19(suppl):3.
116. 116. Belardinelli R, Balestra S, Cesaretti L, Cianci G, Purcaro A. Long-term moderate exercise training in chronic heart failure: effect on mortality and morbidity. (Abstr.) Eur Heart J 1998;19(suppl):3.
117. 117. Matsuda M, Matsuda Y, Yamagishi T, Takahashi T, Haraguchi M, Tada T, Kusukawa R. Effects of digoxin, propranolol, and verapamil on exercise in patients with chronic isolated atrial fibrillation. Cardiovasc Res 1991;25:453-457.
118. 118. Cirjns HJ, Van den Berg MP, Van Gelder IC, Van Veldhuisen DJ. Management of atrial fibrillation in the setting of heart failure. Eur Heart J 1997; 18(suppl C):C45-C49.
119. 119. Peters KG, Kienzle MG. Severe cardiomyopathy due to chronic rapidly conducted atrial fibrillation: complete recovery after restoration of sinus rhythm. Am J Med 1988;85:242-244.
120. 120. Grogan M, Smith HC, Gersh BJ, Wood DL. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol 1992;69:1570-1573.
121. 121. Shivkumar K, Jafri SM, Gheorghiade M. Antithrombotic therapy in atrial fibrillation: a review of randomized trials with special reference to the Stroke Prevention in Atrial Fibrillation II (SPAF II) trial. Progr Cardiavasc Dis 1996; 38:337-342.
122. 122. Falk RH. A plea for a clinical trial of anticoagulation in dilated cardiomyopathy. Am J Cardiol 1990;65:914-915.
123. 123. Rich MW, Beckham V, Wittenberg C, Leven CL, Freedland KE, Carney RM. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 1995;333:1190-1195.
124. 124. Shah NB, Den E, Ruggerio C, Heidenreich PA, Massie BM. Prevention of hospitalisations for heart failure with an interactive home monitoring program. Am Heart J 1998;135:373-378.
125. 125. Fonarow GC, Stevenson LW, Walden JA, Livingston NA, Steimele AE, Hamilton MA, Moriguchi J, Tillisch JH, Woo MA. Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure. J Am Coll Cardiol 1997;30:725-732.
126. 126. The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337:1576-1583.
127. 127. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, Levine JH, Saksena S, Waldo AL, Wilber D, Brown MW, Heo M, for the Multicenter Automatic Defibrillator Implantation Trial Investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmias. N Engl J Med 1996;335:1933-1940.
128. 128. Pratt CM, Eaton T, Francis M, Woolbert S, Mahmarian J, Roberts R, Young JB. The inverse relationship between baseline left ventricular ejection fraction and outcome of antiarrhythmic therapy: a dangerous imbalance in the risk-benefit ratio. Am Heart J 1989;118:433-440.
129. 129. Herchuelz A, Derenne F, Deger F, Juvent M, van Ganse E, Staroukine M, Verniary A, Boeynaems JM, Douchamps J. Interaction between nonsteroidal anti-inflammatory drugs and loop diuretics: modulation by sodium balance. J Pharmacol Exp Ther 1989;248:1175-1181.
130. 130. Bank AJ, Kubo SH, Rector TS, Heifetz SM. Local forearm vasodilation with intra-arterial administration of enalaprilat in humans. Clin Pharmacol Ther 1991; 50:314-321.
131. 131. Dzau VJ, Packer M, Lilly LS, Swartz SL, Hollenberg NK, Williams GH. Prostaglandins in severe congestive heart failure: relation to activation of the renin-angiotensin system and hyponatremia. N Engl J Med 1984;310:347-352.
132. 132. Gottlieb SS, Robinson S, Krichten CM, Fisher ML. Renal response to indomethacin in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1992;70:890-893.
133. 133. Heerdink ER, Leufkens HG, Herings RM, Ottervanger JP, Stricker BH, Bakker A. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med 1998;158:1108-11 12.
134. 134. Hermann DD, Kuiper JJ, Shabetai R, Carethers DA, Shaw DJ, Greenberg BH. Herbal and nutritional supplement (naturoceutical) use in heart failure patient populations. (Abstr.) J Card Failure 1998;4(suppl 1):53.
135. 135. Ferrari R, DeGiuli F. The propionyl-L-carnitine hypothesis: an alternative approach to treating heart failure. J Card Failure 1997;3:217-224.
136. 136. Hofman-Bang C, Rehnqvist N, Swedberg K, Wiklund I, Astrom H. Coenzyme Q10 as an adjunctive in the treatment of chronic congestive heart failure. The Q10 Study Group. J Card Failure 1995;1:101-107.
137. 137. Ghatak A, Brar MJ, Agarwal A, Goil N, Rastilgi AK, Vaish AK, Sircar AR, Chandra M. Oxy free radical system in heart failure and therapeutic role of oral vitamin E. Intern J Cardiol 1996;57:119-127.
138. 138. Bergh C-H, Isgaard J, Caidahl K, Lomsky M, Hjalmarson Å, Bengtsson B-A. Growth hormone addition for patients with congestive heart failure: a randomized, placebo controlled study with recombinant human growth hormone in patients with congestive heart failure and without growth hormone deficiency. (Abstr.) J Am Coll Cardiol 1998;31(suppl):249A.
139. 139. Brater DC. Diuretic therapy. N Engl J Med 1998;339:387-3957.
140. 140. Cody RJ, Kubo SH, Pickworth KK. Diuretic treatment for the sodium retention of congestive heart failure. Arch Intern Med 1994;154:1905-1914.
141. 141. Patterson JH, Adams KF Jr, Applefeld MM, Corder CN, Masse BR, for the Torsemide Investigators Group. Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion. Pharmacotherapy 1994;14:514-521.
142. 142. Sherman LG, Liang CS, Baumgardner S, Charuzi Y, Chardo F, Kim CS. Piretanide, a potent diuretic with potassium-sparing properties, for the treatment of congestive heart failure. Clin Pharmacol Ther 1986;40:587-594.
143. 143. Wilson JR, Reichek N, Dunkman WB, Goldberg S. Effect of diuresis on the performance of the failing left ventricle in man. Am J Med 1981;70:234-239.
144. 144. Parker JO. The effects of oral ibopamine in patients with mild heart failure: a double-blind placebo controlled comparison to furosemide. Int J Cardiol 1993;40:221-227.
145. 145. Richardson A, Bayliss J, Scriven AJ, Parameshwar J, Poole-Wilson PA, Sutton GC. Doutle-blind comparison of captopril alone against frusemide plus amiloride in mild heart failure. Lancet 1987;2:709-711.
146. 146. The Captopril-Digoxin Multicenter Research Group. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA 1988;259:539-544.
147. 147. Packer M, Medina N, Yushak M, Meller J. Hemodynamic patterns of response during long-term captopril therapy for severe chronic heart failure. Circulation 1983;68:803-812.
148. 148. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol 1995;25:1154-1161.
149. 149. el-Ebrashy N, el-Dansoury M, Higazi AM. Effect of digitalisation on urinary excretion of water, sodium, potassium and chloride in heart failure. J Egypt Med Assoc 1968;51:638-644.
150. 150. Motwani JG, Fenwick MK, Morton JJ, Struthers AD. Furosemide-induced natriuresis is augmented by ultra-low-dose captopril but not by standard doses of captopril in chronic heart failure. Circulation 1992;86:439-445.
151. 151. Grinstead WC, Francis MJ, Marks GF, Tawa CB, Zoghbi WA, Young JB. Discontinuation of chronic diuretic therapy in stable congestive heart failure secondary to coronary artery disease or to idiopathic dilated cardiomyopathy. Am J Cardiol 1994;73:881-886.
152. 152. Cody RJ, Covit AB, Schaer GL, Laragh JH, Sealey JE, Feldschuh J. Sodium and water balance in chronic congestive heart failure. J Clin Invest 1986;77: 1441-1452.
153. 153. Sackner-Bernstein J, Krum H, Goldsmith RL, Kukin ML, Medina N, Yushak M, Packer M. Should worsening heart failure early after initiation of beta-blocker therapy for chronic heart failure preclude long-term treatment? (Abstr.) Circulation 1995;92(suppl I):I-395.
154. 154. Cody RJ, Franklin KW, Laragh JH. Postural hypotension during tilt with chronic captopril and diuretic therapy of severe congestive heart failure. Am Heart J 1982;103:480-484.
155. 155. Massie B, Kramer B, Haughton F. Postural hypotension and tachycardia during hydralazine-isosorbide dinitrate therapy for chronic heart failure. Circulation 1981;63:658-664.
156. 156. Packer M, Lee WH, Medina N, Yushak M, Kessler PD. Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure. Ann Intern Med 1987;106:346-354.
157. 157. Vasko MR, Cartwright DB, Knochel JP, Nixon JV, Brater DC. Furosemide absorption altered in decompensated congestive heart failure. Ann Intern Med 1985;102:314-318.
158. 158. Brater DC, Chennavasin P, Seiwell R. Furosemide in patients with heart failure: shift in dose-response curves. Clin Pharmacol Ther 1980;28:182-186.
159. 159. Vargo DL, Kramer WG, Black PK, Smith WB, Serpes T, Brater DC. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther 1995; 57:601-609.
160. 160. Epstein M, Lepp BA, Hoffman DS, Levinson R, Potentiation of furosemide by metolazone in refractory edema. Curr Ther Res 1977;21:656-667.
161. 161. Sica DA, Gehr TWB. Diuretic combinations in refractory oedema states: pharmacokinetic-pharmacodynamic relationships. Clin Pharmacokinetics 1996; 30:229-249.
162. 162. Ellison DH. The physiologic basis for diuretic synergism: its role in treating diuretic resistance. Ann Intern Med 1991;114:886-894.
163. 163. Oster JR, Epstein M, Smoller S. Combined therapy with thiazide-type and loop diuretic agents for resistant sodium retention. Ann Intern Med 1983;99:405-406.
164. 164. Steiness E, Olesen KH. Cardiac arrhythmias induced by hypokalaemia and potassium loss during maintenance digoxin therapy. Br Heart J 1976;38:167-172.
165. 165. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, Kubo SH, Rudin-Toretsky E, Yusuf S. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990;82:1724-1729.
166. 166. Packer M. Adaptive and maladaptive actions of angiotensin II in patients with severe congestive heart failure. Am J Kidney Dis 1987;10(suppl I):66-73.
167. 167. Packer M, Lee WH, Kessler PD. Preservation of glomerular filtration rate in human heart failure by activation of the renin-angiotensin system. Circulation 1986;74:766-774.
168. 168. Packer M. Potential role for potassium as a determinant of morbidity and mortality in patients with hypertension and chronic heart failure. Am J Cardiol 1990;65:45E-51E.
169. 169. Swartz SL, Williams GH, Hollenberg NK, Levine L, Dluhy RG, Moore TJ. Captopril-induced changes in prostaglandin production: relationship to vascular responses in normal man. J Clin Invest 1980;65:1257-1264.
170. 170. Brown NJ, Ryder D, Gainer JV, Morrow JD, Nadeau J. Differential effects of angiotensin converting-enzyme inhibitors on the vasodepressor and prostacyclin responses to bradykinin. J Pharmacol Exp Ther 1996;279:703-712.
171. 171. Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-reccptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998;339: 1285-1292.
172. 2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effects of ramipril. Br J Pharmacol 1992;105: 771-772.
173. 1-adrenoreceptor blockade, converting enzyme inhibitor therapy, and angiotensin II subtype 1 receptor blockade on ventricular remodeling in the dog. Circulation 1994;90:3034-3046.
174. 174. McDonald KM, Mock J, D'Aloia A, Parrish T, Hauer K, Francis G, Stillman A, Cohn JN. Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. Circulation 1995;91:2043-2048.
175. 175. Lambert C, Bastien NR, Legault M-F, Juneau A-V. Comparative study of converting enzyme inhibition and angiotensin II receptor antagonism on survival from chronic heart failure in cardiomyopathic hamsters. (Abstr.) Eur Heart J 1998;19 (suppl):132.
176. 176. Schieffer B, Winger A, Meybrunn M, Seitz S, Holtz J, Riede UN, Drexler H. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type I receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation 1994;89:2273-2282.
177. 177. Juillerat L, Nussberger J, Menard J, Mooser V, Christen Y, Waeber B, Graf P, Brunner HR. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension 1990;16:564-572.
178. 178. Hall D, Zeitler H, Rudolph W. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cordial 1992;20:1549-1555.
179. 179. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA. Effect of antiplatelet agents on survival in patients with left ventricular systolic dysfunction. (Abstr.) Circulation 1995;92(suppl I):I-665-I-666.
180. 180. Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). (Abstr.) Am J Cardiol 1997;79:115-119.
181. 181. Captopril Multicenter Research Group. A placebo-controlled trial of captopril in refractory chronic congestive heart failure. Captopril Multicenter Research Group. J Am Coll Cardiol 1983;2:755-763.
182. 182. Sharpe DN, Murphy J, Coxon R, Hannan SF. Enalapril in patients with chronic heart failure: a placebo-controlled, randomized, double-blind study. Circulation 1984;70:271-278.
183. 183. Chalmers JP, West MJ, Cyran J, De La Torre D, Englert M, Kramar M, Lewis GR, Maranhao MF, Myburgh DP, Schuster P, Sialer S, Simon H, Stephens JD, Watson RDS. Placebo-controlled study of lisinopril in congestive heart failure: a multicentre study. J Cardiovasc Pharmacol 1987;9(suppl III):S89-S97.
184. 184. Cleland JG, Dargie HJ, Hodsman GP, Ball SG, Robertson JI, Morton JJ, East BW, Robertson I, Murray GD, Gillen G. Captopril in heart failure: a double-blind controlled trial. Br Heart J 1984;52:530-535.
185. 185. Cleland JG, Dargie HJ, Ball SG, Gillen G, Hodsman GP, Morton JJ, East BW, Robertson I, Ford I, Robertson JI. Effects of enalapril in heart failure: a double-blind study of effects on exercise performance, renal function, hormones, and metabolic state. Br Heart J 1985;54:305-312.
186. 186. Cowley AJ, Rowley JM, Stainer KL, Hampton JR. Captopril therapy for heart failure: a placebo-controlled study. Lancet 1982;2:730-732.
187. 187. Bayliss J, Norell MS, Canepa-Anson R, Reid C, Poole-Wilson P, Sutton G. Clinical importance of the renin-angiotensin system in chronic heart failure: double-blind comparison of captopril and prazosin. BMJ 1985;290:1861-1865.
188. 188. Pflugfelder PW, Baird MG, Tonkon MJ, DiBianco R, Pitt B, for the Quinapril Heart Failure Trial Investigators. Clinical consequences of angiotensin-converting enzyme inhibitor withdrawal in chronic heart failure: a double-blind, placebo-controlled study of quinapril. J Am Coll Cardiol 1993;22:1557-1563.
189. 189. Gundersen T, Swedberg K, Amtorp O, Remes J, Milsson B. Absence of an effect on exercise capacity of 12-weeks treatment with ramipril in patients with moderate congestive heart failure. Eur Heart J 1994;15:1659-1665.
190. 190. Erhardt L, MacLean A, Ilgenfritz JU, Gelperin K, Blumenthal M, for the Fosinopril Efficacy/Safety Trial (FEST) Study Group. Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Eur Heart J 1995;16:1892-1899.
191. 191. Packer M, Medina N, Yushak M. Correction of dilutional hyponatremia in severe chronic heart failure by converting-enzyme inhibition. Ann Intern Med 1984;100:782-789.
192. 192. Packer M, Lee WH, Medina N, Yushak M. Identification of patients with heart failure at risk of potassium retention during converting-enzyme inhibition. (Abstr.) Circulation 1987;76(suppl IV):IV-273.
193. 193. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
194. 194. Conn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, Bhat G, Goldman S, Fletcher RD, Doherty J, Hughes CV, Carson P, Cintron G, Shabetai R, Haakenson C. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-310.
195. 195. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH, Goldman S, Cobb FR, Shah PM, Saunders R, Fletcher RD, Loeb HS, Hughes VC, Baker B. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of the Veterans Administration Cooperative Study. N Engl J Med 1986;314:1547-1552.
196. 196. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-1435.
197. 197. Packer M. Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice? J Am Coll Cardiol 1996; 28:1323-1327.
198. 198. Pacher R, Stanek B, Globits S, Berger R, Hulsmann M, Wutte M, Frey B, Schuller M, Hartter E, Ogris E. Effects of two different enalapril dosages on clinical, haemodynamic and neurohumoral response of patients with severe congestive heart failure. Eur Heart J 1996;17:1223-1232.
199. 199. Vagelos R, Nejedly M, Willson K, Yee YG, Fowler M. Comparison of low-versus high-dose enalapril therapy for patients with severe congesyive heart failure (CHF). (Abstr.) J Am Coll Cardiol 1991;17(suppl A):275A.
200. 200. Wollert KC, Studer R, von Bülow B, Drexler H. Survival after myocardial infarction in the rat: role of tissue angiotensin-converting enzyme inhibition. Circulation 1994;90:2457-2467.
201. 201. Packer M, Poole-Wilson P, Armstrong P, Cleland J, Horowitz J, Massie B, Ryden L. Comparative effects of low-dose versus high-dose lisinopril on survival and major events in chronic heart failure: the Assessment of Treatment with Lisinopril and Survival Study (ATLAS). (Abstr.) Eur Heart J 1998;19(suppl): 142.
202. 202. Spaulding C, Charbonnier B, Cohen-Solal A, Juilliere Y, Kromer EP, Benhamda K, Cador R, Weber S. Acute hemodynamic interaction of aspirin and ticlopidine with enalapril: results of a double-blind, randomized comparative trial. Circulation 1998;98:757-765.
203. 203. Packer M, Kessler PD, Gottlieb SS. Adverse effects of converting-enzyme inhibition in patients with severe congestive heart failure: pathophysiology and management. Postgrad Med J 1986;62(suppl 1):179-182.
204. 204. Packer M, Medina N, Yushak M. Relation between serum sodium concentration and the hemodynamic and clinical responses to converting enzyme inhibition with captopril in severe heart failure. J Am Coll Cardiol 1984;3:1035-1043.
205. 205. Levine TB, Franciosa JA, Vrobel T, Cohn JN. Hyponatraemia as a marker for high renin heart failure. Br Heart J 1982;47:161-166.
206. 206. Packer M, Lee WH, Kessler PD, Medina N, Yushak M, Gottlieb SS, Identification of hyponatremia as a risk factor for the development of functional renal insufficiency during converting enzyme inhibition in severe chronic heart failure. J Am Coll Cardiol 1987;10:837-844.
207. 207. Ljungman S, Kjekshus J, Swedberg K, for the CONSENSUS Trial Study Group. Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS Trial]). Am J Cardiol 1992;70:479-487.
208. 208. Giles TD, Katz R, Sullivan JM, Wolfson P, Haugland M, Kirlin P, Powers E, Rich S, Hackshaw B, Chiaramida A, Rouleau JL, Fisher MB, Pigeon J, Rush JE, for the Multicenter Lisinopril-Captopril Congestive Heart Failure Study Group. Short- and long-acting angiotensin-converting enzyme inhibitors: a randomized trial of lisinopril versus captopril in the treatment of congestive heart failure. J Am Coll Cardiol 1989;13:1240-1247.
209. 209. Packer M, Lee WH, Medina N, Yushak M, Kessler PD, Gottlieb SS. Influence of diabetes mellitus on changes in left ventricular performance and renal function produced by converting enzyme inhibition in patients with severe chronic heart failure. Am J Med 1987;82:1119-1126.
210. 210. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy: a review of the literature and pathophysiology. Ann Intern Med 1992;117:234-242.
211. 1-adrenoreceptor subtypes mediating vasoconstriction in rabbit cutaneous resistance arteries. Br J Pharmacol 1997;122:825-832.
212. 1B adrenoceptors mediate renal tubular sodium and water reabsorption in the rat. Br J Pharmacol 1994;111:819-824.
213. 213. Hasenfuss G, Holubarsch C, Blanchard EM, Mulieri LA, Alpert NR, Just H. Influence of isoproterenol on myocardial energetics: experimental and clinical investigations. Basic Res Cardiol 1989;84(suppl 1):147-155.
214. 214. Simons M, Donwing SE. Coronary vasoconstriction and catecholamine cardiomyopathy. Am Heart J 1985;109:297-304.
215. 1A-adrenergic receptor subtype mediates biochemical, molecular, and morphologic features of cultured myocardial cell hypertrophy. J Biol Chem 1993;268:15374-15380.
216. 1-adrenergic receptor subtype is responsible for delayed after depolarizations and triggered activity during simulated ischemia and reperfusion of isolated canine Purkinje fibers. Circulation 1991;84:1732-1740.
217. 217. Kaumann AJ, Sanders L. Both beta 1- and beta 2-adrenoceptors mediate catecholamine-evoked arrhythmias in isolated human atrium. Naunyn-Schmiedebergs Arch Pharmacol 1993;348:536-540.
218. 2-adrenergic stimulation in animals susceptible to sudden death. Circulation 1997;96:1914-1922.
219. 219. Reid JL, Whyte KF, Struthers AD. Epinephrine-induced hypokalemia: the role of beta adrenoceptors. Am J Cardiol 1986;57(suppl):23F-27F.
220. 220. Kanai AJ, Mesaros S, Finkel MS, Oddis CV, Birder LA, Malinski T. Beta-adrenergic regulation of constitutive nitric oxide synthase in cardiac myocytes. Am J Physiol 1997;273:C1371-C1377.
221. 221. Communal C, Singh K, Pimentel DR, Colucci WS. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the β-adrenergic pathway. Circulation 1998;98:1329-1334.
222. 222. Woodley SL, Gilbert EM, Anderson JL, O'Connell JB, Deitchman D, Yanowitz FG, Mealey PC, Volkman K, Renlund DG, Menlove R, Bristow MR. β-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation 1991;84:2426-2441.
223. 223. Fisher ML, Gottlieb SS, Plotnick GD, Greenberg NL, Patten RD, Bennett SK, Hamilton BP. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. J Am Coll Cardiol 1994;23:943-950.
224. 224. Metra M, Nardi M, Giubbini R, Dei Cas L. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1994;24:1678-1687.
225. 225. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol 1995;25:1225-1231.
226. 226. Krum H, Sackner-Bemstein JD, Goldsmith RL, Kukin ML, Schwanz B, Penn J, Medina N, Yushak M, Horn E, Katz SD, Levin HR, Neuberg GW, DeLong G, Packer M. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995;92:1499-1506.
227. 227. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson A, for the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1441-1446.
228. 228. CIBIS Investigators and Committees. A randomized trial of β-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994;90:1765-1773.
229. 229. Cohn JN, Fowler MB, Bristow MR, Colucci WS, Gilbert EM, Kinhal V, Krueger SK, LeJemtel T, Narahara KA, Packer M, Young ST, Holeslaw TL, Lukas MA, for the US Carvedilol Heart Failure Study Group. Safety and efficacy of carvedilol in severe heart failure. J Card Failure 1997;3:173-179.
230. 230. Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger SK, Hershberger R, Uretsky BF, Bowers JA, Sackner-Bernstein JD, Young ST, Holeslaw TL, Lukas MA, for the US Carvedilol Heart Failure Study Group. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996;94:2800-2806.
231. 231. White M, Rouleau J-L, Pericak D, Young J, McKelvie R, Held P, Lindgren E, Yusuf S, on behalf of the RESOLVD Study Group. Effects of metoprolol-CR in patients with ischaemic and dilated cardiomyopathy: the RESOLVD pilot study (phase II). (Abstr.) Eur Heart J 1998;19(suppl):308.
232. 232. Tsuyuki RT, Yusuf S, Rouleau JL, Maggioni AP, McKelvie RS, Wiecek EM, Wang Y, Pogue J, Teo KK, White M, Avezum A Jr, Latini R, Held P, Lindgren E, Probstfield J. Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Can J Cardiol 1997;13:1166-1174.
233. 233. CIBIS II Scientific Committee. Design of the Cardiac Insufficiency Bisoprolol Study II (CIBIS II). Fundam Clin Pharmacol 1997;11:138-142.
234. 234. CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
235. 235. The International Steering Committee. Rationale, design, and organization of the Metoprolol CR/XL Randomized Intervention Trial in Heart Failure (MERIT-HF). Am J Cardiol 1997;80(suppl 9B):54J-58J.
236. 236. MERTT-HF Investigators. Communication with Gottlieb SS, Goldstein S, Wedel H concerning the results of the MERIT-HF Trial. October-November, 1998.
237. 237. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997;349:375-380.
238. 238. FDA Cardiovascular and Renal Drugs Advisory Committee. Presentation of NDA for carvedilol for use in heart failure. Bethesda, Maryland, February 27, 1997.
239. 239. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH, for the US Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-1355.
240. 240. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger R, Kubo SH, Narahara KA, Robenson AD, Krueger S. Effect of carvedilol on LV function and mortality in diabetic versus non-diabetic patients with ischemic or nonischemic dilated cardiomyopathy. (Abstr.) Circulation 1996;94: I-644.
241. 241. Waagstein F, Caidahl K, Wallentin I, Bergh CH. Hjalmarson Å. Long-term β-blockade in dilated cardiomyopathy: effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation 1989;80:551-563.
242. 242. Epstein SE, Braunwald E. The effect of beta adrenergic blockade on patterns of urinary sodium excretion: studies in normal subjects and in patients with heart disease. Ann Intern Med 1966;65:20-27.
243. 243. Weil JV, Chidsey CA. Plasma volume expansion resulting from interference with adrenergic function in normal man. Circulation 1968;37:54-61.
244. 244. Di Lenarda A, Gilbert EM, Olsen SL, Mealey PC, Bristow MR. Acute hemodynamic effects of carvedilol versus metoprolol in idiopathic dilated cardiomyopathy. (Abstr.) J Am Coll Cardiol 1991;17(suppl A):142A.
245. 245. Abraham WT, Tsvetkova T, Lowes BD, Ferguson DA, Gilbert EM, Bristow MR. Carvedilol improves renal hemodynamics in patients with chronic heart failure. (Abstr.) Circulation 1998;98(suppl 1):378-379.
246. 246. Di Lenarda A, Salvatore L, Gregori D, Sinagra G, Sabbadini G, Longaro F, Bernobich E, Klugmann S, Camerini F. Effects of carvedilol on left ventricular function and remodeling in patients with dilated cardiomyopathy with persistent left ventricular dysfunction despite optimal conventional therapy. (Abstr.) J Am Coll Cardiol 1998;31:189A.
247. 247. Metra M, Nodari S, D Aloia A, Bontempi L, Proto A, Rosselli F, Zanini R, Dei Cas L. Effects of chronic β-blockade on the haemodynamics and functional capacity of patients with heart failure: a randomized comparison between metoprolol and carvedilol. (Abstr.) Eur Heart J 1998;19(suppl): 307.
248. 248. Akera T, Baskin SI, Tobin T, Brody TM. Ouabain: temporal relationship between the inotropic effect and the in vitro binding to, and dissociation from, (Na+-K+)-activated ATPase. Naunyn Schmiedebergs Arch Pharmacol 1973; 277:151-162.
249. 249. Thames MD. Acetylstrophanthidin-induced reflex inhibition of canine renal sympathetic nerve activity mediated by cardiac receptors with vagal afferents. Circ Res 1979;44:8-15.
250. 250. Ferguson DW, Berg WJ, Sanders JS, Roach PJ, Kempf JS, Kienzle MG. Sympathoinhibitory responses to digitalis glycosides in heart failure patients: direct evidence from sympathetic neural recordings. Circulation 1989;80:65-77.
251. 251. Torretti J, Hendler E, Weinstein E, Longnecker RE, Epstein FH. Functional significance of Na-K-ATPase in the kidney: effects of ouabain inhibition. Am J Physiol 1972;222:1398-1405.
252. 252. Covit AB, Schaer GL, Sealey JE, Laragh JH, Cody RJ. Suppression of the renin-angiotensin system by intravenous digoxin in chronic congestive heart failure. Am J Med 1983;75:445-447.
253. 253. Gheorghiade M, Ferguson D. Digoxin. A neurohormonal modulator in heart failure? Circulation 1991;84:2181-2186.
254. 254. Dobbs SM, Kenyon WI, Dobbs RJ. Maintenance digoxin after an episode of heart failure: placebo-controlled trial in outpatients. Br Med J 1977;1:749-752.
255. 255. Lee DC, Johnson RA, Bingham JB, Leahy M, Dinsmore RE, Goroll AH, Newell JB, Strauss HW, Haber E. Heart failure in outpatients: a randomized trial of digoxin versus placebo. N Engl J Med 1982;306:699-705.
256. 256. Guyatt GH, Sullivan MJ, Fallen EL, Tihal H, Rideout E, Halcrow S, Nogradi S, Townsend M, Taylor DW. A controlled trial of digoxin in congestive heart failure. Am J Cardiol 1988;61:371-375.
257. 257. German-Austrian Xamoterol Study Group. Double-blind placebo-controlled comparison of digoxin and xamoterol in chronic heart failure. Lancet 1988;1: 489-493.
258. 258. DiBianco R, Shabetai R, Kostuk W, Moran J, Schlant RC, Wright R. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med 1989;320:677-683.
259. 259. Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK, on behalf of the PROVED Investigative Group. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. J Am Coll Cardio 1993;22:955-962.
260. 260. van Veldhuisen DJ, Man in't Veld AJ, Dunselman PH, Lok DJ, Dohmen HJ, Poortermans JC, Withagen AJ, Pasteuning WH, Brouwer J, Lie KI. Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT). J Am Coll Cardiol 1993;22:1564-1573.
261. 261. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-533.
262. 262. David D, Segni ED, Klein HO, Kaplinsky E. Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: beneficial effect of an added beta adrenergic blocking agent. Am J Cardiol 1979;44:1378-1382.
263. 263. Hoeschen RJ, Cuddy TE. Dose-response relation between therapeutic levels of serum digoxin and systolic time intervals. Am J Cardiol 1975;35:469-472.
264. 264. Beller GA, Smith TW, Abelmann WH, Haber E, Hood WB Jr. Digitalis intoxication: a prospective clinical study with serum level correlations. N Engl J Med 1971;284:989-997.
265. 265. Young JB, Gheorghiade M, Packer M, Uretsky N, Hull H, on behalf of the PROVED and RADIANCE Investigators. Are low serum levels of digoxin effective in chronic heart failure? Evidence challenging the accepted guidelines for a therapeutic serum level of the drug. (Abstr.) J Am Coll Cardiol 1993;21: 378A.
266. 266. Arnold SB, Byrd RC, Meister W, Melmon K, Cheitlin MD, Bristow JD, Parmley WW, Chatterjee K. Long-term digitalis therapy improves left ventricular function in heart failure. N Engl J Med 1980;303:1443-1448.
267. 267. Gheorghiade M, Hall VB, Jacobsen G, Alam M, Rosman H, Goldstein S. Effects of increasing maintenance dose of digoxin on left ventricular function and neurohormones in patients with chronic heart failure treated with diuretics and angiotensin-converting enzyme inhibitors. Circulation 1995;92:1801-1807.
268. 268. Statton ML, Irani WN, Hall SA, Marcoux LG, Pae RL, Grayburn PA, Eichhorn EJ. Does digoxin provide additional hemodynamic and autonomic benefit at higher doses in patients with mild to moderate heart failure and normal sinus rhythm? J Am Coll Cardiol 1997;29:1206-1213.
269. 269. Fogelman AM, La Mont JT, Finkelstein S, Rado E, Pearce ML. Fallibility of plasma-digoxin in differentiating toxic from non-toxic patients. Lancet 1971; 2:727-729.
270. 270. Ingelfinger JA, Goldman P. The serum digitalis concentration - does it diagnose digitalis toxicity? N Engl J Med 1976;294:867-870.
271. 271. Hager WD, Fenster P, Mayersohn M, Perrier D, Graves P, Marcus FI, Goldman S. Digoxin-quinidine interaction: pharmacokinetic evaluation. N Engl J Med 1979;300:1238-1241.
272. 272. Klein HO, Lang R, Weiss E, Di Segni E, Libhaber C, Guerrero J, Kaplinsky E. The influence of verapamil on serum digoxin concentration. Circulation 1982;65:998-1003.
273. 273. Paladino JA, Davidson KH, McCall BB. Influence of spironolactone on serum digoxin concentration. JAMA 1984;251:470-471.
274. 274. Weeks CE, Conard GJ, Jvam DC, Fox JM, Chang SF, Paone RP, Lewis GP. The effect of flecainide acetate, a new antiarrhythmic, on plasma digoxin levels. J Clin Pharmacol 1986;26:27-31.
275. 275. Moysey JO, Jaggarao NS, Grundy EN, Chamberlain DA. Amiodarone increases plasma digoxin concentrations. (Abstr.) BMJ 1981;282:272.
276. 276. Woodland C, Verjee Z, Giesbrecht E, Koren G, Ito S. The digoxin-propafenone interaction: characterization of a mechanism using renal tubular cell monolayers. J Pharmacol Exp Ther 1997;283:39-45.
277. 277. Bizjak ED, Mauro VF. Digoxin-macrolide drug interaction. Ann Pharmacother 1997;31:1077-1099.
278. 278. Steiner JF, Robbins LJ, Hammermeister KE, Roth SC, Hammond WS. Incidence of digoxin toxicity in outpatients. Western J Med 1994;161:474-478.
279. 279. Duhme DW, Greenblatt DJ, Koch-Weser J. Reduction in digoxin toxicity associated with measurement of serum levels. A report from the Boston Collaborative Drug Surveillance Program. Ann Intern Med 1974;80:516-519.
280. 280. Bigger JT Jr, Fleiss JL, Rolnitzsky LM, Merab JP, Ferrick KJ. Effect of digitalis treatment on survival after acute myocardial infarction. Am J Cardiol 1985;55:623-630.
281. 281. Mancini DM, Benotti JR, Elkayam U, Francis GS, Hess ML, Massie BM, Rodeheffer RJ, Tandon PK, Packer M, and the PROMISE Investigators and Coordinators. Antiarrhythmic drug use and high serum levels of digoxin are independent adverse prognostic factors in patients with chronic heart failure. (Abstr.) Circulation 1991;84(suppl II):II-243.
282. 282. Cohn JN. Vasodilator therapy for heart failure: the influence of impedance on left ventricular performance. Circulation 1973;48:5-8.
283. 283. Guiha NH, Cohn JN, Mikulic E, Franciosa JA, Limas CJ. Treatment of refractory heart failure with infusion of nitroprusside. N Engl J Med 1974;291: 587-592.
284. 284. Francoisa JA, Mikulic E, Cohn JN, Jose E, Fabie A. Hemodynamic effects of orally administered isosorbide dinitrate in patients with congestive heart failure. Circulation 1974;50:1020-1024.
285. 285. Chatterjee K, Parmley WW, Massie B, Greenberg B, Werner J, Klausner S, Norman A. Oral hydralazine therapy for chronic refractory heart failure. Circulation 1976;54:879-883.
286. 286. Greenberg BH, Massie BM, Brundage BH, Botvinick EH, Parmley WW, Chatterjee K. Beneficial effects of hydralazine in severe mitral regurgitation. Circulation 1978;58:273-279.
287. 287. Franciosa JA, Goldsmith SR, Cohn JN. Contrasting immediate and long-term effects of isosorbide dinitrate on exercise capacity in congestive heart failure. Am J Med 1980;69:559-566.
288. 288. Conradson TB, Ryden L, Ahlmark G, Saetre H, Person S, Nyquist O. Clinical efficacy of oral hydralazine in chronic heart failure. One-year double-blind placebo controlled study. Am Heart J 1984;108:1001-1006.
289. 289. Cowley AJ, McEntegart DJ, Hampton JR, Barnett DB, Bexton RA, Boyle R, Hanley SP, Millan-Craig M, Morris GK, Nicholls AJ, Nicholls DP, Oakley GDP, Thomas RD, Ward C, Wynne RD. Long-term evaluation of treatment of chronic heart failure: a 1-year comparative trial of flosequinan and captopril. Cardiovasc Drug Ther 1994;8:829-836.
290. 290. Franciosa JA, Jordan RA, Wilen MM, Leddy CL. Minoxidil in patients with chronic left heart failure: contrasting hemodynamic and clinical effects in a controlled trial. Circulation 1984;70:63-68.
291. 291. Mitchell GF, Pfeffer MA, Finn PV, Pfeffer JM. Equipotent antihypertensive agents variously affect pulsatile hemodynamics and regression of cardiac hypertrophy in spontaneously hypertensive rats. Circulation 1996;94;2923-2929.
292. 292. Markham RV Jr, Gilmore A, Pettiger WA, Brater DC, Corbett JR, Firth BG. Central and regional hemodynamic effects and neurohormonal consequences of minoxidil in severe congestive heart failure and comparison to hydralazine and nitroprusside. Am J Cardiol 1983;52:774-781.
293. 293. Isnard R, Lechat P, Pousset F, Carayon A, Kalotka H, Chikr H, Salloum J, Thomas D, Komajda M. Hemodynamic and neurohormonal effects of flosequinan in patients with heart failure. Fundam Clin Pharmacol 1997;11:83-89.
294. 294. Elsner D, Kromer EP, Riegger AJ. Hemodynamic, hormonal, and renal effects of the prostacyclin analogue iloprost in conscious dogs with and without heart failure. J Cadiovasc Pharmacol 1990;16:601-608.
295. 295. Massie B, Chatterjee K, Werner J, Greenberg B, Hart R, Parmley WW. Hemodynamic advantage of combined administration of hydralazine orally and nitrates nonparenterally in the vasodilator therapy of chronic heart failure. Am J Cardiol 1977;40:794-801.
296. 296. Pierpont GL, Cohn JN, Franciosa JA. Combined oral hydralazine-nitrate therapy in left ventricular failure. Hemodynamic equivalency to sodium nitroprusside. Chest 1978;73:8-13.
297. 297. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromocyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989;83:1774-1777.
298. 298. Calderone A, Thiak CM, Takahashi N, Chang DLF, Colucci WS. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest 1998;101:812-818.
299. 299. Munzel T, Kurz S, Rajagopalan S, Thoenes M, Berrington WR, Thompson JA, Freeman BA, Harrison DG. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action of an old drug. J Clin Invest 1996;98:1465-1470.
300. 300. Yue T-L, Cheng H-Y, Lysko PG, McKenna PJ, Feuerstein R, Gin JL, Lysko KA, Davis LL, Feuerstein G. Carvedilol, a new vasodilator and beta-adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 1992;263:92-98.
301. 301. Dhalla AK, Hill MF, Singal PK. Role of oxidative stress in transition of hypertrophy to heart failure. J Am Coll Cardiol 1996;28:506-514.
302. 302. Keith M, Geranmayegan A, Sole MJ, Kurian F, Robinson A, Omran AS, Jeejeebhoy KN. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 1998;31:1352-1356.
303. 303. Bauer JA, Fung H-L. Concurrent hydralazine administration prevents nitroglycerin-induced hemodynamic tolerance in experimental heart failure. Circulation 1991;84:35-39.
304. 304. Gogia H, Mehra A, Parikh S, Raman M, Ajit-Uppal J, Johnson JV, Elkayam U. Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure. J Am Coll Cardiol 1995;26:1575-1580.
305. 305. Watanabe H, Kakihara M, Ohtsuka S, Sugishita Y. Preventive effects of carvedilol on nitrate tolerance A randomized, double-blind, placebo-controlled comparative study between carvedilol and arotinolol. J Am Coll Cardiol 1998; 32:1201-1206.
306. 306. Wantanabe H, Kakihana M, Ohtsuka S, Nakagawa K, Yamaguchi I. Randomized, double-blind, placebo-controlled comparative study between carvedilol and metoprolol in the prevention of nitrate tolerance in patients with chronic heart failure. (Abstr.) Circulation 1998;98(suppl I):I-364.
307. 307. Loeb HS, Johnson G, Henrick A, Smith R, Wilson J, Cremo R, Cohn JN. Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 1993;87(suppl VI):VI-78-VI-87.
308. 308. Struthers AD. Angiotensin II receptor antagonists for heart failure. Heart 1998;80:5-6.
309. 309. Gottlieb SS, Dickstein K, Fleck E, Kostis J, Levine TB, LeJemtel T, DeKock M. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 1993; 88:1602-1609.
310. 310. Crozier I, Ikram H, Awan N, Cleland J, Stephen N, Dickstein K, Frey M, Young J, Klinger G, Makris L, Rucinska E for the Losartan Hemodynamic Study Group. Losartan in heart failure. Hemodynamic effects and tolerability. Circulation 1995;91:691-697.
311. 311. Riegger GAJ, George M, Arens H-J. Candesartan cilexetil improves exercise tolerance and symptoms in patients with congestive heart failure. (Abstr.) Circulation 1998;98 (suppl 1): 81-82.
312. 312. Granger C, Ertl G, Kuch J, McMurray J, Rouleau J, Swedberg K, Young J, Yusuf S, Held P, Pfeffer M on behalf of the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Investigators. A randomized trial evaluating tolerability of candesartan cilexetil for patients with congestive heart failure and intolerance to angiotensin converting enzyme inhibitors. (Abstr.) Eur Heart J 1998;19(suppl):133.
313. 313. Klinger G, Jaramillo N, Ikram H, Higginbotham M, Lang R, Kraus D, Washington L, Sharma D, Grossman W. Effects of losartan on exercise capacity, morbidity and mortality in patients with symptomatic heart failure. (Abstr.) J Am Coll Cardiol 1997;29:205A.
314. 314. McKelvie R, Yusuf S, Pericak D, Held P. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD pilot study). (Abstr.) Eur Heart J 1998; 19(suppl): 133.
315. 315. Tonkon M, Awan N, Niazi I, Hanley P, Baruch L, Lin C-S, Costagliola D, Cucinotta G, Wolf RA, Block AJ. Irbesartan combined with conventional therapy including angiotensin converting enzyme inhibitors, in heart failure. (Abstr.) J Am Coll Cardiol 1998;31(suppl):188A.
316. 316. Hamroff G, Blaufarb I, Mancini D, Katz S, Bijou R, Jondeau G, Olivari M-T, Thomas S, LeJemtel T. Clinical benefits of long-term angiotensin II receptor blockade in patients with severe symptoms of congestive heart failure despote full angiotensin converting-enzyme inhibition. (Abstr.) J Am Coll Cardiol 1998;31(suppl):188A.
317. 317. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PI, on behalf of ELITE Study Investigators. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-752.
318. 318. Struthers AD. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Cardiol Fail 1996;2:47-54.
319. 319. Weber KT, Villarreal D. Aldosterone and antialdosterone therapy in congestive heart failure. Am J Cardiol 1993;71:3A-11A.
320. 320. Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995;76:1259-1265.
321. 321. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier C Jr. Mineralcorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998;31:451-458.
322. 322. The RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (The Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 1996;78:902-907.
323. 323. Pitt B. Presentation of the results of the RALES Trial. American Heart Association Scientific Sessions, Dallas, Texas, November 1998.
324. 324. Agostoni PG, De Cesare N, Doria E, Polese A, Tamborini G, Guazzi MD. Afterload reduction: a comparison of captopril and nifedipine in dilated cardiomyopathy. Br Heart J 1986;55:391-399.
325. 325. Tan LB, Murray RG, Littler WA. Felodipine in patients with chronic heart failure: discrepant haemodynamic and clinical effects. Br Heart J 1987;58:122-128.
326. 326. Elkayam U, Amin J, Mehra A, Vasquez J, Weber L, Rahimtoola SH. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation 1990;82:1954-1961.
327. 327. Packer M. Calcium channel blockers in chronic heart failure. The risks of physiologically rational therapy. Circulation 1990;82:2254-2257.
328. 328. Packer M. Pathophysiological mechanisms underlying the adverse effects of calcium channel-blocking drugs in patients with chronic heart failure. Circulation 1989:80(suppl IV):IV-54-IV-67.
329. 329. Cheng CP, Noda T, Nordlander M, Ohno M, Little WC. Comparison of effects of dihydropyridine calcium antagonists on left ventricular systolic and diastolic performance. J Pharmacol Exp Ther 1994;268:1232-1241.
330. 330. Ryman KS, Kubo SH, Lystash J, Stone G, Cody RJ. Effect of nicardipine on rest and exercise hemodynamics in chronic congestive heart failure. Am J Cardiol 1986;58:583-588.
331. 331. Tulenko TN, Laury-Kleintop L, Walter MF, Mason RP. Cholesterol, calcium and atherosclerosis: is there a role for calcium channel blockers in atheroprotection? Int J Cardiol 1997;62(suppl 2):S55-S66.
332. 332. Mason RP, Mak IT, Walter MF, Tulenko TN, Mason PE. Antioxidant and cytoprotective activities of the calcium channel blocker mibefradil. Biochem Pharmacol 1998;55:1843-1852.
333. 333. Elkayam U, Weber L, McKay C, Rahimtoola S. Spectrum of acute hemodynamic effects of nifedipine in severe congestive heart failure. Am J Cardiol 1985;56:560-566.
334. 334. Barjon JN, Rouleau JL, Bichet D, Juneau C, De Champlain J. Chronic renal and neurohumoral effects of the calcium entry blocker nisoldipine in patients with congestive heart failure. J Am Coll Cardiol 1987;9:622-630.
335. 335. Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases lateonset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee and the Multicenter Diltiazem Postinfarction Research Group. Circulation 1991;83:52-60.
336. 336. Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988;319:385-392.
337. 337. Littler WA, Sheridan DJ, on behalf of the UK Study Group. Placebo controlled trial of felodipine in patients with mild to moderate heart failure. Br Heart J 1995;73:428-433.
338. 338. Mohindra SK. Long-acting verapamil and head failure. (Letter.) JAMA 1989;261:994.
339. 339. Gheorghiade M, Hall V, Goldberg AD, Levine TB, Goldstein S. Long-term clinical and neurohormonal effects of nicardipine in patients with severe heart failure on maintenance therapy with angiotensin-convening enzyme inhibitors. (Abstr.) J Am Coll Cardiol 1991;17:274A.
340. 340. Mullins ME, Horowitz BZ, Linden DH, Smith GW, Norton RL, Stump J. Life-threatening interaction of mibefradil and beta-blockers with dihydropyridine calcium channel blockers. JAMA 1998;280:157-158.
341. 341. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller AB, Neuberg GW, Frid D, Wertheimer JH, Cropp AB, DeMets DL, for the Prospective Randomized Amlodipine Survival Evaluation Study Group. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996;335:1107-1114.
342. 342. Cohn JN, Ziesche S, Smith R, Anand I, Dunkman WB, Loeb H, Cintron G, Boden W, Baruch L, Rochin P, Loss L, for the Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-Heft III. Circulation 1997;96:856-863.
343. 343. Levine TB for the MACH-1 Investigators. The design of the Mortality Assessment in Congestive Heart Failure Trial (MACH-1, mibefradil). Clin Cardiol 1997;20:320-326.
344. 344. Elkayam U. Presentation of the results of the MACH-1 Trial. XXI Congress of the European Society of Cardiology, 25 August, 1998.
345. 345. Po AL, Zhang WY. What lessons can be learnt from withdrawal of mibefradil from the market? Lancet 1998;35:1829-1830.
346. 346. Billups SJ, Carter BL. Mibefradil withdrawn from the market. Ann Pharmacother 1998;32:841. Letter.
347. 347. Packer M. Sudden unexpected death in patients with congestive heart failure: a second frontier. Circulation 1985;72:681-685.
348. 348. Kjekshus J. Arrhythmias and mortality in congestive heart failure. Am J Cardiol 1990;65:4231-481.
349. 349. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321: 406-412.
350. 350. The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992;327:227-233.
351. 351. Gottlieb SS, Kukin ML, Medina N, Yushak M, Packer M. Comparative hemodynamic effects of procainamide, tocainide and encainide in severe chronic heart failure. Circulation 1990;81:860-864.
352. 352. Packer M. Hemodynamic consequences of antiarrhythmic drug therapy in patients with chronic heart failure. J Cardiovasc Electrophysiol 1991;2(suppl): S240-S247.
353. 353. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a meta-analysis of randomized control trials. Circulation 1990;82:1106-1116.
354. 354. Hansteen V, Moinichen E, Lorentsen E, Andersen A, Strom O, Soiland K, Dyrbekk D, Refsum AM, Tromsdal A, Knudsen K, Eika C, Bakken J Jr, Smith P, Hoff PI. One year's treatment with propranolol after myocardial infarction: preliminary report of Norwegian multicentre trial. BMJ 1982;284:155-160.
355. 355. Du XJ, Esler MD, Dart AM. Sympatholytic action of intravenous amiodarone in the rat heart. Circulation 1995;91:462-470.
356. 356. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R, for Grupo de Estudio de la Sobrevida en la Insufieiencia Cardiaca en Argentina (GESICA). Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994;344:493-498.
357. 357. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, Massie BM, Colling C, Lazzeri D, for the Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmias. N Engl J Med 1995;333: 77-82.
358. 358. Massie BM, Fisher SG, Radford M, Deedwania PC, Singh BN, Fletcher RD, Singh SN. Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. CHF-STAT Investigators. Circulation 1996;93:2128-2134.
359. 359. Naccarelli GV, Rinkenberger RL, Dougherty AH, Fitzgerald DM. Adverse effects of amiodarone. Med Toxicol Adverse Drug Exp 1989;4:246-253.
360. 360. Greene BW, Graham EL, Werner JA, Sears GK, Gross BW, Gorham JP, Kudenchuk PJ, Trobaugh GB. Toxic and therapeutic effects of amiodarone in the treatment of cardiac arrhythmias. J Am Coll Cardiol 1983;2:1114-1128.
361. 361. Waldo AL, Camm AJ, DeRuyter H, Friedman PL, MacNeil DJ, Pauls JF, Pitt B, Pratt CM, Schwartz PJ, Veltri EP, for the SWORD Investigators. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996;348:7-12.
362. 362. Julian DG, Prescott RJ, Jackson FS, Szekely P. Controlled trial of sotalol for one year after myocardial infarction. Lancet 1982;1:1142-1147.
363. 363. Danish Investigations on Arrhythmia and Mortality ON Dofetilide. Dofetilide in patients with left ventricular dysfunction and either heart failure or acute myocardial infarction: rationale, design, and patient characteristics of the DIAMOND studies. Clin Cardiol 1997;20:704-710.
364. 364. Torp-Pedersen for the Danish Investigations of Arrhythmia and Mortality on Dofetilide (DIAMOND) Study Group. Dofetilide: a new class III antiarrhythmic drug which is safe in patients with congestive heart failure. (Abstr.) J Am Coll Cardiol 1998;31;160A.
365. 365. Fuster V, Gersh BJ, Giuliani ER, Tajik AJ, Brandenberg RO, Frye RL. The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol 1981;47:525-531.
366. 366. Stratton JR, Nemanich JW, Johannessen KA, Resnick AD. Fate of left ventricular thrombi in patients with remote myocardial infarction or idiopathic cardiomyopathy. Circulation 1988;78:1388-1393.
367. 367. Jafri SM. Hypercoagulability in heart failure. Semin Thromb Hemost 1997; 23:543-545.
368. 368. Dunkman WB, Johnson GR, Carson PE, Bhat G, Farrell L, Cohn JN for the V-HeFT VA Cooperative Studies Group. Incidence of thromboembolic events in congestive heart failure. Circulation 1993;87(suppl VI):94-101.
369. 369. Dunkman WB. Thromboembolism and antithrombotic therapy in congestive heart failure. J Cardiovasc Risk 1995;2:107-117.
370. 370. Cioffi G, Pozzoli M, Forni G, Franchini M, Opasich C, Cobelli F, Tavazzi L. Systemic thromboembolism in chronic heart failure. A prospective study in 406 patients. Eur Heart J 1996;17:1381-1389.
371. 371. Baker DW, Wright RF. Management of heart failure. IV. Anticoagulation for patients with heart failure due to left ventricular systolic dysfunction. JAMA 1994;272:1614-1618.
372. 372. Katz SD. Left ventricular thrombus and the incidence of thromboembolism in patients with congestive heart failure: Can clinical factors identify patients at increased risk? J Cardiovasc Risk 1995;2:97-102.
373. 373. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA. Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1998;31:749-753.
374. 374. Dries DL, Domanski MJ, Waclawiw MA, Gersh BJ. Effect of antithrombotic therapy on risk of sudden coronary death in patients with congestive heart failure. Am J Cardiol 1997;79:909-913.
375. 375. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990;323:147-152.
376. 376. Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomized trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998;351:233-241.
377. 377. Stratton JR, Resnick AD. Increased embolic risk in patients with left ventricular thrombi. Circulation 1987;75:1004-1011.
378. 378. Leier CV. Comparative systemic and regional hemodynamic effects of dopamine and dobutamine in patients with cardiomyopathic heart failure. Circulation 1978;58:466-475.
379. 379. Simonton CA, Chatterjee K, Cody RJ, Kubo SH, Leonard D, Daly P, Rutman H. Milrinone in congestive heart failure: acute and chronic hemodynamic and clinical evaluation. J Am Coll Cardiol 1985;6:453-459.
380. 380. Longhini C, Ansani L, Musacci GF, Aggio S, Baracca E, Toselli T, Ghirardi P. Peripheral hemodynamic effects of ibopamine in patients with congestive heart failure. A placebo-controlled double-blind study. Cardiovasc Drug Ther 1989;3: 199-202.
381. 381. Roubin GS, Choong CY, Devenish-Meares S, Sadick NN, Fletcher PJ, Kelly DT, Harris PJ. Beta-adrenergic stimulation of the failing left ventricle: a double-blind, randomized trial of sustained oral therapy with prenalterol. Circulation 1984;69:955-962.
382. 382. Glover DR, Wather CG, Murray RG, Petch MC, Muir AL, Littler WA. Are the clinical benefits of oral prenalterol in ischaemic heart failure due to beta blockade? A six-month randomised double-blind comparison with placebo. Br Heart J 1985;53:208-215.
383. 383. Weber KT, Andrews V, Janicki JS, Likoff M, Reichek N. Pirbuterol, an oral beta-adrenergic receptor agonist, in the treatment of chronic cardiac failure. Circulation 1982;66:1262-1267.
384. 384. Massie B, Bourassa M, DiBianco R, Hess M, Konstam M, Likoff M, Packer M. Long-term oral amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial. Circulation 1985;71:963-971.
385. 385. DiBianco R, Shabetai R, Silverman BD, Leier CV, Benotti JR. Oral amrinone for the treatment of chronic congestive heart failure: results of a multicenter randomized double-blind and placebo-controlled withdrawal study. J Am Coll Cardiol 1984;4:855-866.
386. 386. Uretsky BF, Jessup M, Konstam MA, Dec GW, Leier CV, Benotti J, Murali S, Hermann HC, Sandberg JA. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Circulation 1990;82:774-780.
387. 387. Narahara KA for the Western Enoximone Study Group. Oral enoximone in chronic heart failure: a placebo-controlled randomized trial. Am Heart J 1991; 121:1471-1479.
388. 388. Goldberg AD, Nicklas J, Goldstein S for the Imazodan Research Group. Effectiveness of imazodan for treatment of chronic congestive heart failure. Am J Cardiol 1991;68:631-636.
389. 389. Colucci WS, Sonnenblick EH, Adams KE, Berk M, Brozena SC, Cowley AJ, Grabicki JM, Kubo SA, LeJemtel T, Littler WA, Shabetai R, Shannon J, Starling MR, Touchon RC, Wasserman AG for the Milrinone Multicenter Trials Investigators. Efficacy of phosphodiesterase inhibition with milrinone in combination with converting-enzyme inhibitors in patients with heart failure. J Am Coll Cardiol 1993;22:113A-118A.
390. 390. Cadel A, Brusoni B, Pirelli P, Osculati G, Rovati A, Fanciulli R, Carati L, Valagussa F. Effect of digoxin, placebo and ibopamine on exercise tolerance and cardiac rhythm of patients with chronic post-infarct left ventricular failure. Arzneimittelforschung 1986;36:376-379.
391. 391. Feldman AM, Brislow MR, Parmley WW, Carson PE, Pepine CJ, Gilbert EM, Strobeck JE, Hendrix GH, Powers ER, Bain RP, White BG for the Vesnarinone Study Group. Effects of vesnarinone on morbility and mortality in patients with heart failure. N Engl J Med 1993;329:149-155.
392. 392. Lubsen J, Just H, Hjalmarsson AC, La Framboise D, Remme WJ, Heinrich-Nols J, Dumont JM, Seed P. Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial. Heart 1996;76:223-231.
393. 393. Cohn JN, Goldstein SO, Greenberg BH, Lorell BH, Bourge RC, Jaski BE, Gottlieb SO, McGrew F, DeMets D, White BG. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. N Engl J Med 1998;339:1810-1816.
394. 394. Applefeld MM, Newman KA, Sutton FJ, Reed WP, Roffman DS, Talesnick BS, Grove WR. Outpatient dobutamine and dopamine infusions in the management of chronic heart failure: clinical experience in 21 patients. Am Heart J 1987;114:589-595.
395. 395. Cesario D, Clark J, Maisel A. Beneficial effects of intermittent home administration of the inotrope/vasodilator milrinone in patients with end-stage congestive heart failure: a preliminary study. Am Heart J 1998;135:121-129.
396. 396. Harjai KJ, Mehra MR, Ventura HO, Lapeyre YM, Murgo JP, Stapleton DD, Smart FW. Home inotropic therapy in advanced heart failure: cost analysis and clinical outcomes. Chest 1997;112:1298-1303.
397. 397. Sindone AP, Keogh AM, MacDonald PS, McCosker CJ, Kaan AF. Continuous home ambulatory intravenous inotropic drug therapy in severe heart failure: safety and cost efficacy. Am Heart J 1997;134:889-900.
398. 398. Miller LW, Merkle EJ, Hermann V. Outpatient dobutamine for end-stage congestive heart failure. Crit Care Med 1990;18:S30-S33.
399. 399. Dies F, Krell MJ, Whitlow P, Liang CS, Goldenberg I, Applefeld MM, Gilbert EM. Intermittent dobutamine in ambulatory outpatients with chronic cardiac failure. (Abstr.) Circulation 1986;74(suppl II):II-138.
400. 400. Elis A, Bental T, Kimchi O, Ravid M, Lishner M. Intermittent dobutamine treatment in patients with chronic refractory congestive heart failure: a randomised, double-blind, placebo-controlled study. Clin Pharmacol Ther 1998;63:682-685.
401. 401. FDA Cardiovascular and Renal Drugs Advisory Committee. Discussion on use of intravenous inotropic therapy for congestive heart failure. Bethesda, Maryland. January 27, 1998.
402. 402. Lewis EF, Johnson PA, Johnson W, Collins CM, Flavell CM, Griffin LM, Stevenson LW. Heart failure patients express strong polarity of preference for either quality of life or survival. (Abstr.) Circulation 1998;98(suppl I):I-866.
403. 403. Stevenson LW. Inotropic therapy for heart failure. N Engl J Med 1998;339: 1848-1850.
404. 404. Jondeau G, Dubourg O, Delorme G, Arnal JF, Chikli F, Kamour L, Dumas C, Bourdarias JP. Oral enoximone as a substitute for intraveous catecholamine support in end-stage congestive heart failure. Eur Heart J 1994;15:242-246.